Skip to main content
Clinical Trials/ACTRN12622001555741
ACTRN12622001555741RecruitingPhase 4

A double-blinded randomized controlled clinical trial to examine the hearing outcome of intratympanic dexamethasone injection compared with placebo control in subjects who experienced a sudden onset of sensorineural hearing loss

niversity of Melbourne0 sites200 target enrollmentStarted: December 16, 2022Last updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Recruiting
Sponsor
Enrollment
200

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomised controlled trial
Primary Purpose
Treatment
Masking
Blinded (masking used)

Eligibility Criteria

Ages
18 Years to o limit (—)
Sex
All

Inclusion Criteria

  • 1. Idiopathic sudden sensorineural hearing loss (ISSNHL) defined as a history of a sudden decrease in hearing; not exceeding seven days in duration.
  • 2. A sensorineural hearing loss demonstrable on a pure-tone audiogram at the time of entry into the trial (a 20 dB or more hearing loss in at least three frequencies compared to the healthy ear).
  • 3. No otological pathological history or examination findings.
  • 4. Absence of other neurological signs except the eighth cranial nerve defect.

Exclusion Criteria

  • 1. All other types of sensorineural hearing loss, or conductive forms of hearing impairment.
  • 2. A history of fluctuating sensorineural hearing loss.
  • 3. Medical conditions rendering prescription of steroids unsafe. For example, patients with hypertension, diabetes, active peptic disease, pregnancy, chronic infections, uncompensated heart disease, recent surgery or psychiatric disease.

Investigators

Sponsor
niversity of Melbourne

Similar Trials